59 related articles for article (PubMed ID: 36913260)
1. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
[TBL] [Abstract][Full Text] [Related]
2. Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma.
Cui X; Zhao J; Li G; Yang C; Yang S; Zhan Q; Zhou J; Wang Y; Xiao M; Hong B; Yi K; Tong F; Tan Y; Wang H; Wang Q; Jiang T; Fang C; Kang C
Cancer Commun (Lond); 2023 Dec; 43(12):1326-1353. PubMed ID: 37920878
[TBL] [Abstract][Full Text] [Related]
3. Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
Vincent CA; Nissen I; Dakhel S; Hörnblad A; Remeseiro S
BMC Cancer; 2023 Oct; 23(1):945. PubMed ID: 37803333
[TBL] [Abstract][Full Text] [Related]
4. Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma.
Loriguet L; Morisse MC; Dremaux J; Collet L; Attencourt C; Coutte A; Boone M; Sevestre H; Galmiche A; Gubler B; Chauffert B; Trudel S
BMC Cancer; 2018 Oct; 18(1):964. PubMed ID: 30305059
[TBL] [Abstract][Full Text] [Related]
5. Characterization and comparison of human glioblastoma models.
Schulz JA; Rodgers LT; Kryscio RJ; Hartz AMS; Bauer B
BMC Cancer; 2022 Aug; 22(1):844. PubMed ID: 35922758
[TBL] [Abstract][Full Text] [Related]
6. Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets.
Li J; Shih LK; Brat DJ
Cancer Res; 2024 May; 84(9):1379-1381. PubMed ID: 38330148
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive somatic mutational analysis in glioblastoma: Implications for precision medicine approaches.
Azimi P; Karimpour M; Yazdanian T; Totonchi M; Ahmadiani A
PLoS One; 2024; 19(1):e0295698. PubMed ID: 38166029
[TBL] [Abstract][Full Text] [Related]
8. Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics.
Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
[TBL] [Abstract][Full Text] [Related]
9. Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors.
Friedman JS; Jun T; Rashidipour O; Huang KL; Ellis E; Kadaba P; Belani P; Nael K; Tsankova NM; Sebra R; Hormigo A
Cancer Immunol Immunother; 2023 Jun; 72(6):1893-1901. PubMed ID: 36707424
[TBL] [Abstract][Full Text] [Related]
10. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?
Ge M; Zhu Y; Wei M; Piao H; He M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188996. PubMed ID: 37805108
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.
Furnari FB; Cloughesy TF; Cavenee WK; Mischel PS
Nat Rev Cancer; 2015 May; 15(5):302-10. PubMed ID: 25855404
[TBL] [Abstract][Full Text] [Related]
12. EGFR, the Lazarus target for precision oncology in glioblastoma.
Lin B; Ziebro J; Smithberger E; Skinner KR; Zhao E; Cloughesy TF; Binder ZA; O'Rourke DM; Nathanson DA; Furnari FB; Miller CR
Neuro Oncol; 2022 Dec; 24(12):2035-2062. PubMed ID: 36125064
[TBL] [Abstract][Full Text] [Related]
13. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
Álvarez-Vázquez A; San-Segundo L; Cerveró-García P; Flores-Hernández R; Ollauri-Ibáñez C; Segura-Collar B; Hubert CG; Morrison G; Pollard SM; Lathia JD; Sánchez-Gómez P; Tabernero A
Neuro Oncol; 2024 Mar; ():. PubMed ID: 38507464
[TBL] [Abstract][Full Text] [Related]
14. Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.
Ziani-Zeryouh A; Wouters R; Thirion G; Vandenbrande K; Vankerckhoven A; Berckmans Y; Bevers S; Verbeeck J; De Keersmaecker K; Coosemans A; Riva M
Methods Cell Biol; 2024; 183():381-397. PubMed ID: 38548420
[TBL] [Abstract][Full Text] [Related]
15. A troublesome burden, the amplification of EGFR in glioblastoma!
Lobbous M; Nabors LB
Neuro Oncol; 2020 May; 22(5):594-595. PubMed ID: 32144420
[No Abstract] [Full Text] [Related]
16. In vivo functional characterization of EGFR variants identifies novel drivers of glioblastoma.
Yu K; Kong K; Lozzi B; Luna-Figueroa E; Cervantes A; Curry R; Mohila CA; Rao G; Jalali A; Mills GB; Scott KL; Deneen B
Neuro Oncol; 2023 Mar; 25(3):471-481. PubMed ID: 36044040
[TBL] [Abstract][Full Text] [Related]
17. Almonertinib as a neoadjuvant therapy for patients with a superior pulmonary sulcus tumor with activated EGFR mutation: A case report.
Kang K; Jiang Z; Kai J; Chen S; Xiong F
Exp Ther Med; 2023 Dec; 26(6):564. PubMed ID: 37954117
[TBL] [Abstract][Full Text] [Related]
18. Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes.
Pant A; Lim M
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2312277120. PubMed ID: 37672559
[No Abstract] [Full Text] [Related]
19. Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations.
Shi C; Zhang C; Fu Z; Liu J; Zhou Y; Cheng B; Wang C; Li S; Zhang Y
Acta Pharm Sin B; 2023 Jun; 13(6):2613-2627. PubMed ID: 37425047
[TBL] [Abstract][Full Text] [Related]
20. Intracranial complete remissions in an aumolertinib-treated
Shan X; Wu Y; Liu J
Transl Cancer Res; 2023 Feb; 12(2):434-438. PubMed ID: 36915577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
